Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin

BACKGROUND: There is no proven primary preventive strategy for doxorubicin‐induced subclinical cardiotoxicity (DISC), especially among patients without a cardiovascular (CV) risk. We investigated the primary preventive effect on DISC of the concomitant use of angiotensin receptor blockers (ARBs) or...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Myunhee, Chung, Woo‐Baek, Lee, Ji‐eun, Park, Chan‐Seok, Park, Woo‐Chan, Song, Byung‐Joo, Youn, Ho‐Joong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209607/
https://www.ncbi.nlm.nih.gov/pubmed/33998163
http://dx.doi.org/10.1002/cam4.3956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209607/
https://www.ncbi.nlm.nih.gov/pubmed/33998163
http://dx.doi.org/10.1002/cam4.3956

Ejemplares similares